Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The pharmaceuticals market in Angola has been experiencing significant growth in recent years due to various factors.
Customer preferences: Angolan customers are increasingly demanding high-quality pharmaceutical products that are effective and affordable. With a growing middle class, there is an increasing demand for branded drugs, which are perceived to be of better quality than generic drugs. However, the majority of the population still prefers generic drugs due to their affordability.
Trends in the market: The pharmaceuticals market in Angola has been growing due to the increasing prevalence of chronic diseases such as diabetes, hypertension, and cancer. This has led to increased demand for drugs to manage these conditions. Additionally, there has been an increase in government spending on healthcare, which has led to increased access to healthcare services and medication.
Local special circumstances: The pharmaceuticals market in Angola faces various challenges, including a lack of local manufacturing capacity, which has led to a heavy reliance on imports. Additionally, there is a lack of regulatory oversight, which has led to the proliferation of counterfeit drugs in the market. However, the government has been taking steps to address these challenges, including investing in local manufacturing capacity and strengthening regulatory oversight.
Underlying macroeconomic factors: Angola is one of the fastest-growing economies in Africa, with a rapidly expanding middle class. This has led to increased demand for healthcare services and medication. Additionally, the government has been investing heavily in infrastructure development, which has led to increased access to healthcare services and medication. However, the country is heavily dependent on oil exports, which has led to significant fluctuations in the economy due to changes in oil prices. This has led to challenges in maintaining a stable healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)